https://scholars.lib.ntu.edu.tw/handle/123456789/487371
標題: | Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma | 作者: | ANN-LII CHENG Hsiung C.A. Su I.-J. PEI-JER CHEN Chang M.-C. Tsao C.-J. Kao W.-Y. Uen W.-C. CHIH-HUNG HSU HWEI-FANG TIEN Chao T.-Y. Chen L.-T. Whang-Peng J. |
公開日期: | 2003 | 出版社: | W.B. Saunders | 卷: | 37 | 期: | 6 | 起(迄)頁: | 1320-1328 | 來源出版物: | Hepatology | 摘要: | Reactivation of hepatitis is one of the most serious complications of chemotherapy in lymphoma patients who are carriers of the hepatitis B virus (HBV). Glucocorticoids are linked to increased risk of HBV reactivation. This study seeks to clarify whether removal of glucocorticoids from chemotherapy regimens may decrease the risk of HBV reactivation. Eligible patients were seropositive for hepatitis B surface antigen (HBsAg) and had histologically proven non-Hodgkin's lymphomas for which intensive chemotherapy was indicated. Patients were randomized to receive either ACE (epirubicin, cyclophosphamide, and etoposide) or PACE (prednisolone + ACE). A total of 50 patients were enrolled, 25 each for the ACE and PACE arms. The cumulative incidence of HBV reactivation at 9 months after starting chemotherapy was 38% and 73% for ACE and PACE arm, respectively (P = .03). The degree of clinical hepatitis was significantly more severe in the PACE arm: 11 patients (44%) in the PACE and 3 patients (13%) in the ACE arm had ALT elevation more than 10-fold of normal (P = .025), and 7 patients (28%) in the PACE and 1 patient (4%) in the ACE arm had icteric hepatitis (P = .049). Complete remission of tumors occurred in 11 (46%) patients in the PACE and 8 (35%) patients in the ACE arm (P = .556). The estimated overall survival rate at 46 months was 68% in the PACE arm and 36% in the ACE arm, respectively (P = .18). In conclusion, steroid-free chemotherapy decreases the incidence and severity of HBV reactivation in HBsAg-positive lymphoma patients. However, further research is needed to evaluate whether steroid-free chemotherapy may confer a less satisfactory control of lymphoma. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984575715&doi=10.1053%2fjhep.2003.50220&partnerID=40&md5=1f65d89ae4d5e120ccacb22205d72197 https://scholars.lib.ntu.edu.tw/handle/123456789/487371 |
ISSN: | 0270-9139 | DOI: | 10.1053/jhep.2003.50220 | SDG/關鍵字: | cyclophosphamide; epirubicin; etoposide; glucocorticoid; hepatitis B surface antigen; ifosfamide; methotrexate; prednisolone; adolescent; adult; aged; article; cancer chemotherapy; cancer regression; cancer survival; clinical article; controlled study; disease course; disease severity; drug contraindication; female; hepatitis B; Hepatitis B virus; human; incidence; liver histology; male; nonhodgkin lymphoma; priority journal; risk factor; risk management; statistical analysis; survival rate; virus carrier; virus reactivation |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。